Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Revolution Medicines, Inc.RVMD · Entity 606 | SVP & General Counsel | September 25, 2026 | September 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Revolution Medicines, Inc.
Report date September 25, 2026 · Filed September 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 51,776 |
Reported balance
After 2026-09-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-25 · Sale · Disposed 765 · Balance 51,776 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026. F2: Includes 37,088 restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026.
F2: Includes 37,088 restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 27, 2024 Filed Mar 28, 2024 20:11 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 700 | $30.38 | $21,269.01 |
DisclosureSEC source: 0001610717-24-000189 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,174 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 27, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $30.16 to $30.85, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 48,972 restricted stock units. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 20:45 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,252 | $31.58 | $39,542.17 |
DisclosureSEC source: 0001610717-24-000174 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,874 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · shares: Pursuant to an automatic sell-to-cover imposed by the terms of the RSUs award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F3 · balance_after: Includes 48,972 RSUs. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:54 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantStock Option (Right to Buy) · Derivative | 73,500 | $0.00 Strike: $29.80 | $0.00 |
DisclosureSEC source: 0001610717-24-000132 · form4.xml · derivative · entry 2 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,500 Underlying: Common Stock · 73,500 shares Expires 2034-02-28 F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2024 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:54 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | GrantCommon Stock | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-24-000132 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,126 F1 · balance_after: Includes 52,417 restricted stock units. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 21:12 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,500 | $27.00 | $40,500.00 |
DisclosureSEC source: 0001610717-24-000040 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,126 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 27, 2023. F2 · balance_after: Includes 31,417 restricted stock units. F3 · balance_after: Includes 342 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2023. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 22:08 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,229 | $25.90 | $31,833.19 |
DisclosureSEC source: 0001610717-23-000414 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,284 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · shares: Pursuant to an automatic sell-to-cover imposed by the terms of the RSUs award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F3 · price: This transaction was executed in multiple trades in prices ranging from $25.9017 to $25.915, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4 · balance_after: Includes 31,417 RSUs. Read SEC document |
| November 20, 2023 Filed Nov 20, 2023 23:24 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,500 | $21.70 | $32,544.90 |
DisclosureSEC source: 0001610717-23-000360 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,513 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 27, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $21.38 to $22.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 34,860 restricted stock units. Read SEC document |
| September 28, 2023 Filed Oct 2, 2023 20:12 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 202 | $29.06 | $5,870.10 |
DisclosureSEC source: 0001610717-23-000300 · form4.xml · nonDerivative · entry 2 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,013 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 27, 2023. F4 · price: This transaction was executed in multiple trades in prices ranging from $29.05 to $29.06, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 34,860 restricted stock units. Read SEC document |
| September 28, 2023 Filed Oct 2, 2023 20:12 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,798 | $28.10 | $50,523.62 |
DisclosureSEC source: 0001610717-23-000300 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,215 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 27, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $27.84 to $28.27, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 34,860 restricted stock units. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 20:11 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,214 | $31.31 | $38,011.07 |
DisclosureSEC source: 0001610717-23-000293 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,013 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $31.1026 to $31.3108, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 34,860 RSUs. Read SEC document |
| July 31, 2023 Filed Aug 1, 2023 22:23 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,500 | $26.02 | $39,030.00 |
DisclosureSEC source: 0001610717-23-000219 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,227 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 27, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $25.78 to $26.37, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 38,305 restricted stock units. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 20:24 UTC | Revolution Medicines, Inc. RVMD · Entity 606 | SaleCommon Stock | 1,239 | $25.14 | $31,148.46 |
DisclosureSEC source: 0001610717-23-000192 · form4.xml · nonDerivative · entry 1 Cislini Jeff · CIK 0001969082 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,727 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Includes 370 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2023. F3 · balance_after: Includes 38,305 RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.